Literature DB >> 7022741

Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.

C Mattsson, V Nyberg-Arrhenius, P Wallén.   

Abstract

Mesh:

Substances:

Year:  1981        PMID: 7022741     DOI: 10.1016/0049-3848(81)90254-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  11 in total

1.  Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.

Authors:  S Thorsen; S Müllertz; E Suenson; P Kok
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

Review 2.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

3.  Streptokinase, urokinase, and tissue plasminogen activator: pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis.

Authors:  A S Maizel; J J Bookstein
Journal:  Cardiovasc Intervent Radiol       Date:  1986       Impact factor: 2.740

Review 4.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 5.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

6.  Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.

Authors:  K Kaltoft; L S Nielsen; J Zeuthen; K Danø
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

7.  Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.

Authors:  C Tran-Thang; E K Kruithof; F Bachmann
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.

Authors:  P A Andreasen; L S Nielsen; J Grøndahl-Hansen; L Skriver; J Zeuthen; R W Stephens; K Danø
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

10.  Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.

Authors:  L Skriver; L I Larsson; V Kielberg; L S Nielsen; P B Andresen; P Kristensen; K Danø
Journal:  J Cell Biol       Date:  1984-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.